These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

186 related items for PubMed ID: 19786739

  • 1. Hemoglobin level variability: anemia management among variability groups.
    Gilbertson DT, Peng Y, Bradbury B, Ebben JP, Collins AJ.
    Am J Nephrol; 2009; 30(6):491-8. PubMed ID: 19786739
    [Abstract] [Full Text] [Related]

  • 2. The controversy surrounding hemoglobin and erythropoiesis-stimulating agents: what should we do now?
    Singh AK.
    Am J Kidney Dis; 2008 Dec; 52(6 Suppl):S5-13. PubMed ID: 19010260
    [Abstract] [Full Text] [Related]

  • 3. Hemoglobin level variability: associations with comorbidity, intercurrent events, and hospitalizations.
    Ebben JP, Gilbertson DT, Foley RN, Collins AJ.
    Clin J Am Soc Nephrol; 2006 Nov; 1(6):1205-10. PubMed ID: 17699349
    [Abstract] [Full Text] [Related]

  • 4. Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients.
    Regidor DL, Kopple JD, Kovesdy CP, Kilpatrick RD, McAllister CJ, Aronovitz J, Greenland S, Kalantar-Zadeh K.
    J Am Soc Nephrol; 2006 Apr; 17(4):1181-91. PubMed ID: 16565261
    [Abstract] [Full Text] [Related]

  • 5. It's time to compare anemia management strategies in hemodialysis.
    Coyne DW.
    Clin J Am Soc Nephrol; 2010 Apr; 5(4):740-2. PubMed ID: 20299363
    [Abstract] [Full Text] [Related]

  • 6. Effect of facility-level hemoglobin concentration on dialysis patient risk of transfusion.
    Collins AJ, Monda KL, Molony JT, Li S, Gilbertson DT, Bradbury BD.
    Am J Kidney Dis; 2014 Jun; 63(6):997-1006. PubMed ID: 24315770
    [Abstract] [Full Text] [Related]

  • 7. Protocol adherence and the ability to achieve target haemoglobin levels in haemodialysis patients.
    Chan K, Moran J, Hlatky M, Lafayette R.
    Nephrol Dial Transplant; 2009 Jun; 24(6):1956-62. PubMed ID: 19176685
    [Abstract] [Full Text] [Related]

  • 8. Intravenous iron versus erythropoiesis-stimulating agents: friends or foes in treating chronic kidney disease anemia?
    Kalantar-Zadeh K, Streja E, Miller JE, Nissenson AR.
    Adv Chronic Kidney Dis; 2009 Mar; 16(2):143-51. PubMed ID: 19233073
    [Abstract] [Full Text] [Related]

  • 9. Effect of variability in anemia management on hemoglobin outcomes in ESRD.
    Lacson E, Ofsthun N, Lazarus JM.
    Am J Kidney Dis; 2003 Jan; 41(1):111-24. PubMed ID: 12500228
    [Abstract] [Full Text] [Related]

  • 10. Hemoglobin control, ESA resistance, and regular low-dose IV iron therapy: a review of the evidence.
    Singh A.
    Semin Dial; 2009 Jan; 22(1):64-9. PubMed ID: 19175537
    [Abstract] [Full Text] [Related]

  • 11. Optimizing anemia management in hospitalized patients with end-stage renal disease.
    Heung M, Mueller BA, Segal JH.
    Ann Pharmacother; 2009 Feb; 43(2):276-82. PubMed ID: 19141655
    [Abstract] [Full Text] [Related]

  • 12. The influence of need-based, continuous, low-dose iron replacement on hemoglobin levels in hemodialysis patients treated with erythropoiesis-stimulating agents.
    Malovrh M, Hojs N, Premru V.
    Artif Organs; 2011 Jan; 35(1):63-8. PubMed ID: 20618233
    [Abstract] [Full Text] [Related]

  • 13. Hemoglobin variability in anemia of chronic kidney disease.
    Kalantar-Zadeh K, Aronoff GR.
    J Am Soc Nephrol; 2009 Mar; 20(3):479-87. PubMed ID: 19211716
    [Abstract] [Full Text] [Related]

  • 14. Association of mean weekly epoetin alfa dose with mortality risk in a retrospective cohort study of Medicare hemodialysis patients.
    Weinhandl ED, Gilbertson DT, Collins AJ.
    Am J Nephrol; 2011 Mar; 34(4):298-308. PubMed ID: 21829009
    [Abstract] [Full Text] [Related]

  • 15. Mortality in incident haemodialysis patients: time-dependent haemoglobin levels and erythropoiesis-stimulating agent dose are independent predictive factors in the ANSWER study.
    Fort J, Cuevas X, García F, Pérez-García R, Lladós F, Lozano J, Martín-Malo A, ANSWER study.
    Nephrol Dial Transplant; 2010 Aug; 25(8):2702-10. PubMed ID: 20176608
    [Abstract] [Full Text] [Related]

  • 16. A comprehensive vision for intravenous iron therapy.
    Coyne DW.
    Am J Kidney Dis; 2008 Dec; 52(6 Suppl):S14-20. PubMed ID: 19010257
    [Abstract] [Full Text] [Related]

  • 17. Individualizing decision-making--resurrecting the doctor-patient relationship in the anemia debate.
    Agarwal R.
    Clin J Am Soc Nephrol; 2010 Jul; 5(7):1340-6. PubMed ID: 20448071
    [Abstract] [Full Text] [Related]

  • 18. Causes and consequences of inflammation on anemia management in hemodialysis patients.
    Chawla LS, Krishnan M.
    Hemodial Int; 2009 Apr; 13(2):222-34. PubMed ID: 19432697
    [Abstract] [Full Text] [Related]

  • 19. An economic evaluation of erythropoiesis-stimulating agents in CKD.
    Clement FM, Klarenbach S, Tonelli M, Wiebe N, Hemmelgarn B, Manns BJ.
    Am J Kidney Dis; 2010 Dec; 56(6):1050-61. PubMed ID: 20932621
    [Abstract] [Full Text] [Related]

  • 20. Triumph and tragedy: anemia management in chronic kidney disease.
    Novak JE, Szczech LA.
    Curr Opin Nephrol Hypertens; 2008 Nov; 17(6):580-8. PubMed ID: 18941350
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.